22. A pharmaceutical composition, comprising as an active ingredient the fusion protein as defined in any one of claims 1 to 15, in combination with a pharmaceutically acceptable carrier.

23. The pharmaceutical composition according to claim 22, in a form for parenteral administration.

24. The fusion protein as defined in any one of claims 1 to 15 for use in the treatment of neoplastic diseases in mammals, including humans.

25. ~~A method of treating cancer diseases in mammal, including human, which comprises administration to a subject in a need thereof~~ The use of an anti-neoplastic-effective amount of the fusion protein as defined in claims 1 to 15, or the pharmaceutical composition as defined in claims 22 or 23 in the manufacture of a medicament for treating cancer diseases in mammal, including human.